Therapeutics targeting innate and adaptive immune systems

Ventyx Biosciences is a clinical-stage biopharmaceutical company dedicated to developing innovative oral medicines aimed at treating autoimmune and inflammatory diseases. The company focuses on selectively modulating key immune targets to create differentiated therapies that transition the treatment landscape from injectables to oral medications. Their current pipeline includes four clinical-stage programs targeting specific immune pathways, including NLRP3, S1P1R, and TYK2. By leveraging their expertise in drug discovery and development, Ventyx aims to address significant unmet medical needs with novel oral therapies that can effectively manage various inflammatory conditions.

The technologies employed by Ventyx encompass a comprehensive approach to drug discovery, integrating medicinal and process chemistry, computational chemistry, structural biology, and pharmacology. Their methodology emphasizes an iterative lead optimization process that combines rational and empirical drug design, enabling the selection of candidates with high potency and selectivity for their immunology targets. Additionally, Ventyx utilizes relevant screening methods, including human cellular assays and biomarker-driven approaches, to predict the efficacy and therapeutic window of their compounds in clinical trials. This streamlined process allows Ventyx to efficiently advance multiple small-molecule product candidates from preclinical stages to clinical development, ultimately aiming to deliver effective oral therapies to patients.

United States

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company’s lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

Cancer

Central Nervous System (CNS)

Digestive System Diseases

Endocrine System Diseases

Inflammatory disorders

Metabolic Diseases

Nervous System Diseases

Ventyx Biosciences

Ulcerative colitis

VTX002 is an oral, selective S1P1R modulator in development for UC.
Sphingosine 1 phosphate (S1P) receptors are G-Protein Coupled &nbsp;Receptors involved in the modulation of numerous biological responses, &nbsp;including lymphocyte trafficking from lymph nodes to the peripheral &nbsp;blood. S1P receptor 1 (S1P1R) modulators sequester lymphocytes in the &nbsp;lymph nodes, resulting in fewer immune cells in the circulating blood to &nbsp;exacerbate inflammation.

Tamuzimod (VTX002) (S1P1R modulator)

Cryopyrin-Associated Autoinflammatory Syndromes

Recurrent pericarditis

VTX2735 (NLRP3 inhibitor)

Parkinson's disease

VTX3232, a novel CNS-penetrant NLRP3 inhibitor

VTX3232 

Crohns disease

VTX958 is an oral, selective allosteric inhibitor of TYK2 with the &nbsp;potential to address a broad range of immune-mediated diseases, such as &nbsp;psoriasis, psoriatic arthritis, Crohn’s disease and lupus.
In autoimmune diseases, such as psoriasis, lupus, inflammatory &nbsp;bowel diseases, rheumatoid arthritis, multiple sclerosis and ankylosing &nbsp;spondylitis, overactive cytokine pathways drive the disease pathology. &nbsp;The essential role of TYK2 signaling in these diseases has been shown by &nbsp;studies of naturally occurring genetic mutations in humans and in &nbsp;genetic deletion/knockout animal disease models. An oral, selective TYK2 &nbsp;inhibitor could play a critical role in offering a well-balanced &nbsp;therapy that dampens harmful immune responses in these diseases while &nbsp;preserving protective immunity against pathogens.

Ventyx Biosciences

Company Details